For research use only. Not for therapeutic Use.
SAK3 is a potent T-type voltage-gated Ca2+ channels (T-VGCCs) enhancer. SAK3 enhances Cav3.1 and Cav3.3 T-type Ca2+ channel currents. Acute SAK3 administration improves memory deficits in olfactory-bulbectomized mice[1]. SAK3 inhibits amyloid β plaque formation in APP-KI mice by activating the proteasome activity[2].
SAK3 (0.01-10 nM) significantly enhances Cav3.1 or Cav3.3 currents in neuro2A cells ectopically expressing Cav3.1 or Cav3.3, respectively[1].
Acute SAK3 (0.5 mg/kg) oral administration promotes acetylcholine (ACh) release in hippocampal CA1 via T-VGCC stimulation via enhancing T-type Ca2+ channel[1].
| Catalog Number | I014670 |
| CAS Number | 1256269-87-0 |
| Synonyms | ethyl 8′-methyl-2′,5-dioxo-2-piperidin-1-ylspiro[cyclopentene-3,3′-imidazo[1,2-a]pyridine]-1-carboxylate |
| Molecular Formula | C20H23N3O4 |
| Purity | ≥95% |
| InChI | InChI=1S/C20H23N3O4/c1-3-27-18(25)15-14(24)12-20(16(15)22-9-5-4-6-10-22)19(26)21-17-13(2)8-7-11-23(17)20/h7-8,11H,3-6,9-10,12H2,1-2H3 |
| InChIKey | WZHBYTVHUFURPY-UHFFFAOYSA-N |
| SMILES | CCOC(=O)C1=C(C2(CC1=O)C(=O)N=C3N2C=CC=C3C)N4CCCCC4 |
| Reference | [1]. Yasushi Yabuki, et al. Pharmacological properties of SAK3, a novel T-type voltage-gated Ca2+ channel enhancer. Neuropharmacology. 2017 May 1;117:1-13. [2]. Jing Xu, et al.T-Type Ca2+ Enhancer SAK3 Activates CaMKII and Proteasome Activities in Lewy Body Dementia Mice Model. Int J Mol Sci. 2021 Jun 8;22(12):6185. |
